This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Google Scholar Articles by Bozaoglu, K. Articles by Jowett, J. B.M. PubMed PubMed Citation Articles by Bozaoglu, K. Articles by Jowett, J. B.M. Related Collections Lipid Diabetes and Insulin Metabolism

Chemerin Is Associated with Metabolic Syndrome Phenotypes in a Mexican-American Population

Metabolic Research Unit (K.B., D.S., K.W.), School of Medicine, Deakin University, Waurn Ponds, Victoria 3217, Australia; Genomics Laboratory (K.A.S., N.C., J.B.M.J.), Baker IDI-Heart & Diabetes Institute, Prahran, Victoria 3004, Australia; Department of Genetics (J.E.C., A.G.C., M.C.M., D.L.R., J.L.V., J.W.M., J.B.), Southwest Foundation for Biomedical Research, San Antonio, Texas 78227; ChemGenex Pharmaceuticals (G.C.), Geelong, Victoria 3220, Australia; and Verva Pharmaceuticals (K.W.), Waurn Ponds, Victoria 3217, Australia

Address all correspondence and requests for reprints to: Ken Walder, Metabolic Research Unit, Deakin University, Pigdons Road, Waurn Ponds, Victoria 3218, Australia. E-mail: walder{at}deakin.edu.au.

Context: Chemerin is a novel adipokine previously associated with metabolic syndrome phenotypes in a small sample of subjects from Mauritius.

Objective: The aim of the study was to determine whether plasma chemerin levels were associated with metabolic syndrome phenotypes in a larger sample from a second, unrelated human population.

Design, Setting, Patients, and Intervention: Plasma samples were obtained from the San Antonio Family Heart Study (SAFHS), a large family-based genetic epidemiological study including 1431 Mexican-American individuals. Individuals were randomly sampled without regard to phenotype or disease status. This sample is well-characterized for a variety of phenotypes related to the metabolic syndrome.

Main Outcomes: Plasma chemerin levels were measured by sandwich ELISA. Linear regression and correlation analyses were used to determine associations between plasma chemerin levels and metabolic syndrome phenotypes.

Results: Circulating chemerin levels were significantly higher in nondiabetic subjects with body mass index (BMI) greater than 30 kg/m² compared with those with a BMI below 25 kg/m² (P < 0.0001). Plasma chemerin levels were significantly associated with metabolic syndrome-related parameters, including BMI (P < 0.0001), fasting serum insulin (P < 0.0001), triglycerides (P < 0.0001), and high-density lipoprotein cholesterol (P = 0.00014), independent of age and sex in nondiabetic subjects.

Conclusion: Circulating chemerin levels were associated with metabolic syndrome phenotypes in a second, unrelated human population. This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome.

This article has been cited by other articles:

				H. Sell, J. Laurencikiene, A. Taube, K. Eckardt, A. Cramer, A. Horrighs, P. Arner, and J. Eckel Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells Diabetes, December 1, 2009; 58(12): 2731 - 2740. [Abstract] [Full Text] [PDF]